Skip to main content
. 2017 Jun 26;19(8):628–636. doi: 10.1016/j.neo.2017.04.007

Figure 5.

Figure 5

Rituximab reduces the incidence of CD45+ cells in ovarian cancer PDXs.

Real-time PCR was used to screen for expression of human CD45 in 277 early generation PDX models. The results shown in those pie charts are relative expression of human CD45 with or without rituximab treatment. The incidence of CD45-positive engrafted tumors decreased from 86.3% to 5.6% after the addition of rituximab.